Skip to main content

Table 1 Baseline characteristics of the patients

From: Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination

Characteristics TACE plus apatinib plus camrelizumab (n = 80) early combination group (n = 45) late combination group (n = 35)
Age (years), median (IQR) 52 (46–62) 53 (48–60) 50 (43–63)
Age group (years)
  < 65 66 (82.5) 37 (82.2) 29 (82.9)
  ≥ 65 14 (17.5) 8 (17.8) 6 (17.1)
Sex
 Male 66 (82.5) 36 (80.0) 30 (85.7)
 Female 14 (17.5) 9 (20.0) 5 (14.3)
ECOG PS
 0 34 (42.5) 15 (33.3) 19 (54.3)
 1 46 (57.5) 30 (66.7) 16 (45.7)
Child–Pugh class
 A 58 (72.5) 29 (64.4) 29 (82.9)
 B 22 (27.5) 16 (35.6) 6 (17.1)
Co-treatment time
 Early combination 45 (56.3) 45 (100.0) 0 (0.0)
 Late combination 35 (43.8) 0 (0.0) 35 (100.0)
Extrahepatic metastases 44 (55.0) 27 (60.0) 17 (48.6)
Macrovascular invasion 47 (58.8) 30 (66.7) 17 (48.6)
BCLC stage
 B 13 (16.3) 4 (8.9) 9 (25.7)
 C 67 (83.7) 41 (91.1) 26 (74.3)
Liver Cirrhosis 70 (87.5) 38 (84.4) 32 (91.4)
Hepatitis B 65 (81.3) 35 (77.8) 30 (85.7)
Tumor distribution
 Single 13 (16.3) 7 (15.6) 6 (17.1)
 Multiple 67 (83.8) 38 (84.4) 29 (82.9)
 Tumor size (cm, mean ± SD) 9.7 ± 4.7 10.0 ± 4.5 9.3 ± 5.0
  < 10 cm 45 (56.3) 25 (55.6) 20 (57.1)
  ≥ 10 cm 35 (43.8) 20 (44.4) 15 (42.9)
Laboratory parameters
 RBC (10^9/L, mean ± SD) 4.1 ± 0.8 4.0 ± 0.8 4.2 ± 0.9
 Hb (g/L), median (IQR) 128 (110–138) 129 (112–136) 128 (110–139)
 Platelet (10^9/L), median (IQR) 163 (119–228) 151 (111–210) 181 (144–372)
 WBC (10^12/L, mean ± SD) 5.8 ± 1.9 5.5 ± 1.8 6.3 ± 2.0
 Neutrophils (10^9/L, mean ± SD) 3.9 ± 1.7 3.6 ± 1.4 4.2 ± 1.9
 Lymphocyte (10^9/L, mean ± SD) 1.3 ± 0.5 1.2 ± 0.5 1.4 ± 0.5
 NLR, median (IQR) 2.8 (2.0–4.5) 2.9 (2.2–4.6) 2.8 (1.8–4.4)
 ALT (U/L), median (IQR) 38 (25–57.5) 38.5 (25–58) 35 (25–56.5)
 AST (U/L), median (IQR) 46 (34.5–84.5) 61.5 (39–105) 41 (33.5–54)
 TBIL (μmmol/L), median (IQR) 14.4 (10.8–19) 15.2 (10.8–21.7) 13.4 (10.7–17.4)
 ALP (U/L), median (IQR) 134 (102–203.5) 147 (109–224) 118 (89.5–169.5)
 TBA (μmol/L), median (IQR) 7.8 (4.1–14.3) 8.35 (4.1–17) 7.7 (4.5–13.1)
 ALB (g/L, mean ± SD) 36.4 ± 4.9 35.2 ± 4.1 38.0 ± 5.3
AFP (ng/mL)
  < 200 28 (35.0) 14 (31.1) 14 (12.3)
  ≥ 200 52 (65.0) 31 (68.9) 21 (60.0)
  1. Data are median (range) or N (%). TACE transcatheter arterial chemoembolization
  2. ECOG PS Eastern Cooperative Oncology Group Performance Status, BCLC Barcelona Clinic Liver Cancer, RBC red blood cell, Hb Hemoglobin, WBC white blood cell, NLR Neutrophils/ Lymphocyte, ALT Alanine aminotransferase, AST Aspartate aminotransferase, TBIL total bilirubin, ALP alkaline phosphatase, TBA total bile acid, ALB albumin, AFP alpha-fetoprotein
  3. Early combination was defined as treatment with apatinib and camrelizumab after the first or second TACE. Late combination was defined as having had at least three times TACE before receiving treatment with apatinib and camrelizumab